PHAT
HealthcarePhathom Pharmaceuticals, Inc.
$10.34+0.12 (+1.13%)
Prev Close
$10.22
Open
$10.34
High
$10.47
Low
$10.06
Volume
1.01M
Market Cap
$877.4M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Phathom Pharmaceuticals, Inc. (PHAT) has been dominated by selling, with 4 insider purchases totaling $217.0K and 12 insider sales totaling $2.08M. The most recent insider transaction was by Basta Steven L (President and CEO), who sold $80.5K worth of shares on Feb 10, 2026. Phathom Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $877.4M.
Buys (12M)
4
$217.0K
Sells (12M)
12
$2.08M
Net Activity
Net Seller
$1.86M
Active Insiders
6
last 12 mo
PHAT Price Chart
PHAT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026↗ | Basta Steven L | President and CEO | Sell | 6,277 | $12.82 | $80.5K | 0 |
| Feb 10, 2026↗ | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 1,535 | $12.82 | $19.7K | 0 |
| Jan 21, 2026↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 776 | $13.61 | $10.6K | 0 |
| Dec 18, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 230 | $16.28 | $3.7K | 0 |
| Dec 17, 2025↗ | Basta Steven L | President and CEO | Sell | 31,502 | $15.36 | $483.9K | 0 |
| Dec 17, 2025↗ | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 7,703 | $15.36 | $118.3K | 0 |
| Nov 28, 2025↗ | Basta Steven L | President and CEO | Sell | 48,375 | $15.62 | $755.6K | 0 |
| Nov 3, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 524 | $13.51 | $7.1K | 0 |
| Sep 25, 2025↗ | Basta Steven L | President and CEO | Sell | 48,375 | $11.66 | $564.1K | 0 |
| Sep 5, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 461 | $12.09 | $5.6K | 0 |
| Jul 16, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 1,692 | $8.36 | $14.2K | 0 |
| May 21, 2025↗ | Topper James N | Director | Buy | 3,780 | $3.86 | $14.6K | 0 |
| May 13, 2025↗ | Topper James N | Director | Buy | 7,420 | $3.30 | $24.5K | 0 |
| May 9, 2025↗ | Topper James N | Director | Buy | 48,203 | $3.17 | $152.9K | 0 |
| May 6, 2025↗ | Parikh Asit | Director | Buy | 10,000 | $2.50 | $25.0K | 0 |
| Apr 7, 2025↗ | Henderson Molly | CFO and CBO | Sell | 3,678 | $4.55 | $16.7K | 0 |
| Mar 13, 2025↗ | Parikh Asit | Director | Buy | 10,000 | $4.42 | $44.2K | 0 |
| Jul 17, 2024↗ | Curran Terrie | President and Chief Executive | Sell | 33,848 | $11.72 | $396.7K | 377,734 |
| Jul 17, 2024↗ | Henderson Molly | CFO and CBO | Sell | 4,325 | $11.72 | $50.7K | 99,447 |
| Jul 17, 2024↗ | Nabulsi Azmi | Chief Operating Officer | Sell | 10,901 | $11.72 | $127.8K | 240,421 |
| Mar 26, 2024↗ | Curran Terrie | President and Chief Executive | Sell | 16,851 | $9.11 | $153.5K | 410,784 |
| Jan 25, 2024↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 3,703,703 | $8.10 | $30.00M | 3,755,580 |
| Jan 22, 2024↗ | Henderson Molly | CFO and CBO | Sell | 6,307 | $7.75 | $48.9K | 98,698 |
| Nov 21, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,127 | $7.24 | $15.4K | 103,061 |
| Nov 8, 2023↗ | Parikh Asit | Director | Buy | 7,500 | $7.81 | $58.6K | 55,000 |
| Nov 3, 2023↗ | Henderson Molly | CFO and CBO | Sell | 12,492 | $8.88 | $110.9K | 116,869 |
| Jun 5, 2023↗ | Henderson Molly | CFO and CBO | Sell | 1,960 | $11.41 | $22.4K | 68,506 |
| May 23, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,110 | $12.87 | $27.2K | 70,466 |
| Apr 11, 2023↗ | Nabulsi Azmi | Chief Operating Officer | Buy | 10,000 | $8.26 | $82.6K | 99,567 |
| Apr 11, 2023↗ | Parikh Asit | Director | Buy | 1,000 | $7.55 | $7.5K | 23,500 |
| Apr 7, 2023↗ | Curran Terrie | President and Chief Executive | Buy | 12,919 | $7.82 | $101.0K | 188,290 |
| Apr 7, 2023↗ | Henderson Molly | CFO and CBO | Sell | 3,439 | $7.27 | $25.0K | 72,576 |
| Mar 3, 2023↗ | Curran Terrie | President and Chief Executive | Sell | 1,436 | $8.54 | $12.3K | 175,371 |
| Mar 3, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,032 | $8.53 | $17.3K | 76,015 |
| Feb 14, 2023↗ | Parikh Asit | Director | Buy | 5,000 | $7.73 | $38.7K | 22,500 |
| Jan 20, 2023↗ | Curran Terrie | President and Chief Executive | Sell | 5,821 | $8.20 | $47.7K | 176,807 |
| Jan 12, 2023↗ | Parikh Asit | Director | Buy | 5,000 | $7.00 | $35.0K | 17,500 |
| Nov 23, 2022↗ | Curran Terrie | President and Chief Executive | Sell | 1,526 | $9.60 | $14.6K | 83,720 |
| Nov 23, 2022↗ | Henderson Molly | CFO and CBO | Sell | 2,159 | $9.60 | $20.7K | 43,341 |
| May 16, 2022↗ | Curran Terrie | President and Chief Executive | Buy | 20,500 | $7.41 | $151.8K | 64,595 |
| May 16, 2022↗ | Nabulsi Azmi | Chief Operating Officer | Buy | 20,000 | $8.16 | $163.3K | 785,700 |
| May 16, 2022↗ | Parikh Asit | Director | Buy | 12,500 | $8.00 | $100.0K | 12,500 |
| Mar 16, 2022↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 18 | $19.00 | $342.00 | 7,459,290 |
| Nov 8, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 1,000,001 | $20.85 | $20.85M | 1,100,000 |
| Oct 8, 2021↗ | Socks David A | Director | Sell | 18,000 | $32.58 | $586.4K | 1,213,880 |
| Sep 23, 2021↗ | Socks David A | Director | Sell | 18,000 | $32.63 | $587.4K | 1,233,770 |
| Aug 18, 2021↗ | Socks David A | Director | Sell | 18,000 | $31.25 | $562.5K | 1,261,140 |
| Jul 9, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 2,609 | $35.05 | $91.4K | 871,305 |
| Jul 6, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 8,326 | $35.16 | $292.7K | 874,014 |
| Jun 29, 2021↗ | Socks David A | Director | Sell | 40,000 | $34.05 | $1.36M | 1,275,060 |
Showing 1–50 of 75
1 / 2
PHAT Insider Buying Activity
The following table shows recent insider purchases of Phathom Pharmaceuticals, Inc. (PHAT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 21, 2025↗ | Topper James N | Director | Buy | 3,780 | $3.86 | $14.6K | 0 |
| May 13, 2025↗ | Topper James N | Director | Buy | 7,420 | $3.30 | $24.5K | 0 |
| May 9, 2025↗ | Topper James N | Director | Buy | 48,203 | $3.17 | $152.9K | 0 |
| May 6, 2025↗ | Parikh Asit | Director | Buy | 10,000 | $2.50 | $25.0K | 0 |
| Mar 13, 2025↗ | Parikh Asit | Director | Buy | 10,000 | $4.42 | $44.2K | 0 |
| Nov 8, 2023↗ | Parikh Asit | Director | Buy | 7,500 | $7.81 | $58.6K | 55,000 |
| Apr 11, 2023↗ | Nabulsi Azmi | Chief Operating Officer | Buy | 10,000 | $8.26 | $82.6K | 99,567 |
| Apr 11, 2023↗ | Parikh Asit | Director | Buy | 1,000 | $7.55 | $7.5K | 23,500 |
| Apr 7, 2023↗ | Curran Terrie | President and Chief Executive | Buy | 12,919 | $7.82 | $101.0K | 188,290 |
| Feb 14, 2023↗ | Parikh Asit | Director | Buy | 5,000 | $7.73 | $38.7K | 22,500 |
| Jan 12, 2023↗ | Parikh Asit | Director | Buy | 5,000 | $7.00 | $35.0K | 17,500 |
| May 16, 2022↗ | Curran Terrie | President and Chief Executive | Buy | 20,500 | $7.41 | $151.8K | 64,595 |
| May 16, 2022↗ | Nabulsi Azmi | Chief Operating Officer | Buy | 20,000 | $8.16 | $163.3K | 785,700 |
| May 16, 2022↗ | Parikh Asit | Director | Buy | 12,500 | $8.00 | $100.0K | 12,500 |
PHAT Insider Selling Activity
The following table shows recent insider sales of Phathom Pharmaceuticals, Inc. (PHAT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026↗ | Basta Steven L | President and CEO | Sell | 6,277 | $12.82 | $80.5K | 0 |
| Feb 10, 2026↗ | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 1,535 | $12.82 | $19.7K | 0 |
| Jan 21, 2026↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 776 | $13.61 | $10.6K | 0 |
| Dec 18, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 230 | $16.28 | $3.7K | 0 |
| Dec 17, 2025↗ | Basta Steven L | President and CEO | Sell | 31,502 | $15.36 | $483.9K | 0 |
| Dec 17, 2025↗ | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 7,703 | $15.36 | $118.3K | 0 |
| Nov 28, 2025↗ | Basta Steven L | President and CEO | Sell | 48,375 | $15.62 | $755.6K | 0 |
| Nov 3, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 524 | $13.51 | $7.1K | 0 |
| Sep 25, 2025↗ | Basta Steven L | President and CEO | Sell | 48,375 | $11.66 | $564.1K | 0 |
| Sep 5, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 461 | $12.09 | $5.6K | 0 |
| Jul 16, 2025↗ | Breedlove Robert Charles | Principal Accounting Officer | Sell | 1,692 | $8.36 | $14.2K | 0 |
| Apr 7, 2025↗ | Henderson Molly | CFO and CBO | Sell | 3,678 | $4.55 | $16.7K | 0 |
| Jul 17, 2024↗ | Curran Terrie | President and Chief Executive | Sell | 33,848 | $11.72 | $396.7K | 377,734 |
| Jul 17, 2024↗ | Henderson Molly | CFO and CBO | Sell | 4,325 | $11.72 | $50.7K | 99,447 |
| Jul 17, 2024↗ | Nabulsi Azmi | Chief Operating Officer | Sell | 10,901 | $11.72 | $127.8K | 240,421 |
| Mar 26, 2024↗ | Curran Terrie | President and Chief Executive | Sell | 16,851 | $9.11 | $153.5K | 410,784 |
| Jan 25, 2024↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 3,703,703 | $8.10 | $30.00M | 3,755,580 |
| Jan 22, 2024↗ | Henderson Molly | CFO and CBO | Sell | 6,307 | $7.75 | $48.9K | 98,698 |
| Nov 21, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,127 | $7.24 | $15.4K | 103,061 |
| Nov 3, 2023↗ | Henderson Molly | CFO and CBO | Sell | 12,492 | $8.88 | $110.9K | 116,869 |
| Jun 5, 2023↗ | Henderson Molly | CFO and CBO | Sell | 1,960 | $11.41 | $22.4K | 68,506 |
| May 23, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,110 | $12.87 | $27.2K | 70,466 |
| Apr 7, 2023↗ | Henderson Molly | CFO and CBO | Sell | 3,439 | $7.27 | $25.0K | 72,576 |
| Mar 3, 2023↗ | Curran Terrie | President and Chief Executive | Sell | 1,436 | $8.54 | $12.3K | 175,371 |
| Mar 3, 2023↗ | Henderson Molly | CFO and CBO | Sell | 2,032 | $8.53 | $17.3K | 76,015 |
| Jan 20, 2023↗ | Curran Terrie | President and Chief Executive | Sell | 5,821 | $8.20 | $47.7K | 176,807 |
| Nov 23, 2022↗ | Curran Terrie | President and Chief Executive | Sell | 1,526 | $9.60 | $14.6K | 83,720 |
| Nov 23, 2022↗ | Henderson Molly | CFO and CBO | Sell | 2,159 | $9.60 | $20.7K | 43,341 |
| Mar 16, 2022↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 18 | $19.00 | $342.00 | 7,459,290 |
| Nov 8, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 1,000,001 | $20.85 | $20.85M | 1,100,000 |
| Oct 8, 2021↗ | Socks David A | Director | Sell | 18,000 | $32.58 | $586.4K | 1,213,880 |
| Sep 23, 2021↗ | Socks David A | Director | Sell | 18,000 | $32.63 | $587.4K | 1,233,770 |
| Aug 18, 2021↗ | Socks David A | Director | Sell | 18,000 | $31.25 | $562.5K | 1,261,140 |
| Jul 9, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 2,609 | $35.05 | $91.4K | 871,305 |
| Jul 6, 2021↗ | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 8,326 | $35.16 | $292.7K | 874,014 |
| Jun 29, 2021↗ | Socks David A | Director | Sell | 40,000 | $34.05 | $1.36M | 1,275,060 |
PHAT Insiders
Similar Stocks to PHAT
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B